Stamey T A, Condy M, Mihara G
N Engl J Med. 1977 Apr 7;296(14):780-3. doi: 10.1056/NEJM197704072961403.
We examined bacterial persistence and resistance in the vaginal and fecal flora of 28 women who received a total of 253 months of daily low-dosage prophylaxis with nitrofurantoin macrocystals (100 mg per day) or trimethoprim-sulfamethoxazole (40 and 200 mg respectively). During trimethoprim-sulfamehtoxazole prophylaxis, 8.5% of monthly vaginal and 27% of monthly fecal cultures grew Escherichia coli, as compared to 36 and 96%, respectively for nitrofurantoin macrocrystals. Esch. coli resistant to nitrofurantoin occurred in two of 95 fecal cultures during therapy, and Esch. coli resistant to trimethoprim-sulfamethoxazole in 16 of 182 (8.8%) fecal cultures. In the 12 months before treatment, 92 episodes of recurrent urinary infection occurred, as compared to six during treatment (none occurred on trimethoprim-sulfamethoxazole). These results confirm the value of trimethoprim-sulfamethoxazole prophylaxis for high-risk patient with recurrent urinary infections. Prophylaxis with nitrofurantoin macrocrystals seems adequate for less severe problems of reinfection.
我们对28名女性的阴道和粪便菌群中的细菌持续性及耐药性进行了研究,这些女性接受了总计253个月的每日低剂量呋喃妥因大晶体(每日100毫克)或复方新诺明(分别为40毫克和200毫克)预防治疗。在复方新诺明预防治疗期间,每月阴道培养物中有8.5%、粪便培养物中有27%培养出大肠杆菌,而呋喃妥因大晶体治疗时这两个比例分别为36%和96%。治疗期间,95份粪便培养物中有两份培养出对呋喃妥因耐药的大肠杆菌,182份(8.8%)粪便培养物中有16份培养出对复方新诺明耐药的大肠杆菌。治疗前的12个月中发生了92次复发性尿路感染,治疗期间发生了6次(复方新诺明治疗期间无感染发生)。这些结果证实了复方新诺明预防治疗对复发性尿路感染高危患者的价值。呋喃妥因大晶体预防治疗对于不太严重的再感染问题似乎足够。